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Four-color flow cytometry bypasses limitations 
of IG/TCR polymerase chain reaction for minimal 
residual disease detection in certain subsets of 
children with acute lymphoblastic leukemia 
The level of minimal residual disease(MRD) has emerged as a powerfulprognostic indicator in the monitor-
ing of childhood acute lymphoblastic
leukemia (ALL) and is currently incorpo-
rated to refine risk-assignment in most
treatment protocols.1-4 MRD studies con-
ducted so far have shown that patients
with MRD ≥10-2 after completion of
induction therapy have a very high risk of
relapse. On the other hand, patients with
very low MRD levels (<10-4) at the end of
induction were found to have a very good
prognosis following some,5 but not all,6
treatment protocols. For this reason,
patients with high MRD levels receive a
rapid intensification of chemotherapy
while no change in treatment has been
introduced for patients with low levels of
MRD in currently ongoing French trials.
This risk-adapted stratification requires
MRD assays that have a sensitivity of at
least 10-3 and that can yield results reason-
ably quickly (within 40-50 days from diag-
nosis). To fulfil these objectives, a rapid
assay for quantifying MRD, based on
immunoglobulin (IG)/T-cell receptor
(TCR) genes rearrangement amplification
using competitive polymerase chain reac-
tion (PCR) and Genescan analysis7 was
chosen for routine analysis, instead of the
more sensitive allele-specific real-time
PCR, taking advantage of the simplicity,
rapidity, reliability and low-cost effective-
ness of the former. Moreover, the results
of this method are strongly correlated
with those obtained in our previous stud-
ies (hybridization to clono-specific
probes).6,7 Flow cytometry (FC) techniques
also offer the advantage of speed.8 Indeed,
PCR and FC have been shown to be equal-
ly suitable methods for detecting MRD,
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Background and Objectives. Competitive immunoglobulin/T-cell receptor polymerase-
chain reaction (PCR) analysis with fluorescent detection is a rapid, cheap and repro-
ducible method for quantifying minimal residual disease (MRD), which is well adapted
to the recognition of high-risk childhood acute lymphoblastic leukemia (ALL). We aimed
at defining whether flow cytometry (FC) techniques can bypass limitations of PCR for
MRD determination.
Design and Methods. We analyzed 140 remission samples from 91 patients using
both competitive PCR amplification of antigen-receptor genes and four-color FC identi-
fication of leukemia immunophenotype. These methods were chosen with the aim of
detecting at least 0.1% blasts. 
Results. MRD was measured using both PCR and FC methods in 123 samples and the
two methods provided concordant results in 119 of them (97%). Moreover, three out
of the four discordant results appeared minor since MRD was detectable by both meth-
ods, but at different levels. In 12 of 13 samples from nine patients, mainly infants with
early CD10– and/or t(4;11) B-cell ALL and children with immature T-cell ALL, MRD could
be determined using FC whereas PCR failed. Conversely, FC methods were unfeasible
due to inappropriate leukemia immunophenotype in three additional children (including
two with T-cell ALL) for whom PCR successfully provided MRD results.
Interpretation and Conclusions. The MRD results provided by FC techniques were high-
ly concordant with those of competitive PCR. Moreover, the applicability of FC appeared
higher in certain ALL subsets, although the appropriateness of this technique in terms
of outcome prediction remains to be demonstrated.  
Key words: acute lymphoblastic leukemia, flow cytometry, PCR, minimal residual
disease.
Haematologica 2005; 90:1516-1523
©2005 Ferrata Storti Foundation
Acute Lymphoblastic Leukemia • Research Paper
although neither is always applicable and both suffer
technical limitations.2,3,8-10 However the question of
whether there is any advantage from combining both
techniques for the determination of MRD remains
unclear. Although several studies combining both
methods reported comparable MRD results, their
conclusion was usually that both methods should be
coupled.8,11-14 However, in routine laboratory practice,
remission samples are sometimes too small to allow
both techniques to be conducted. Moreover, such a
strategy may appear rather expensive. Therefore, we
compared multi-color FC methods and IG/TCR com-
petitive PCR with fluorescent detection for MRD
determination in childhood ALL. We conducted a pil-
lot study of MRD assessment using IGH/TCR-PCR
and FC assays in a series of children with ALL in
whom treatment was rapidly intensified in those
with high levels of MRD (i.e. more than 1% bone
marrow leukemic cells) after completion of induction
chemotherapy, but not reduced in those with the
lowest levels of MRD.
Design and Methods
Patients and treatment
We studied 136 remission bone marrow samples
containing enough cells for dual PCR and FC analysis
obtained from 88 consecutive unselected children,
including 7 infants (<12 months old), with ALL diag-
nosed between 2000 and 2003 in Nantes (n=84) and
in 2003 in Besançon (n=4) University Hospitals.
According to the immunophenotype, there were 76
cases of B-cell ALL (including 7 with negative CD10
expression and 5 with t(4;11) translocation) and 12 of
T-cell ALL. Four additional samples from three chil-
dren with T-cell ALL (including one infant) from
Robert-Debré Hospital (Paris) in whom PCR-MRD
measurements had been unfeasible were selectively
analyzed with FC methods in the Nantes laboratory.
All of the patients were enrolled in three Berlin-
Frankfurt-Munster (BFM)-derived treatment proto-
cols. MRD was assessed at the end of induction (day
35±5) (time-point 1) and consolidation (day 85±25)
(time-point 2) -therapy in 85 and 55 patients, respec-
tively. MRD was measured at the second time-point
in all those cases in which MRD at the first time-
point was > 1% according to the protocol recom-
mendations, as well as in a subset of unselected
patients with a lower MRD level at the first time-
point. Informed consent was obtained from the par-
ents in every case. All the patients were in complete
remission at the time of each MRD determination,
and had less than 5% blasts in bone marrow smears.
Sample collection and preparation
Bone marrow aspirates were collected at diagnosis
and during the follow-up. Ficoll-separated mononu-
clear cells were then separated into two fractions,
one being processed immediately by FC methods in
Nantes or Besançon, the other being frozen and sent
to Paris, in CO2 ice, for PCR analysis. 
PCR assessment of MRD 
PCR reactions allowing detection of the most com-
mon gene combinations of IG heavy chain (FRIII-JH),
TCR d (TCRD) (all combinations involving VD1,
VD2, DD2, DD3, and J1 were amplified in a multi-
plex assay) and TCR g (TCRG) (all combinations
involving VGI, VG9, VG10, VG11, J1, J2, JP1, and JP2
were amplified) were performed on each initial sam-
ple at presentation.15,16 When no proper marker was
available in B-lineage ALL, rearrangements of the
immunoglobulin k (IGK) locus was also investigat-
ed.16 MRD was quantified using a competitive PCR
assay identifying the clonal gene rearrangements of
leukemic blasts by their size without sequencing, as
previously described.7
Briefly, the PCR product corresponding to the blast
rearrangement was analyzed by capillary elec-
trophoresis, detected by fluorescence and visualized
as a peak of separated size using an ABI-PRISM 3100
genetic analyzer (Applied Biosystems, Roissy, France)
and a Genscan 672 program (Applied Biosystems).
The blast level was determined using a competitive
PCR assay based on the co-amplification of an inter-
nal standard homologous to the marker to be quanti-
fied. The result was eventually obtained by compar-
ing the remission (test) sample to a reference sample
with a blast concentration of 0.1%, 0.5%, or 1%
(mixture of polyclonal mononuclear bone marrow
cells and known amounts of the patient’s blasts) and
containing the same amount of the internal standard.
MRD was evaluated with the use of a single mark-
er in 13 cases of B-cell ALL and 2 of T-cell ALL and
with at least two markers in 59 B-cell ALL and 7 T-
cell ALL cases. TCRD and TCRG markers were used,
alone or combined, in 35 and 32 B-cell ALL and in 2
and 7 T-cell ALL patients, respectively. In addition,
IG markers were used alone in 14 cases of B-cell ALL.
FC assessment of MRD
The FC strategy that we used for determination of
MRD derived from the method extensively described
by Campana and Coustan-Smith9 and involved an
identical technical procedure, monoclonal antibody
panel and flow cytometer in the laboratories at
Nantes and Besançon. Mononuclear cells
(1¥106/tube) were stained with four-color combina-
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tions of monoclonal antibodies conjugated with fluo-
rescein isothiocyanate (FITC), phycoerythrin (PE),
allophycocyanin (APC) and peridinin chlorophyll
protein (PerCP) (or phycoerythrin cyanin 5 [PC5]).
Quantitative or qualitative (illegitimate expression)
antigen aberrations of leukemic cells (leukemia-asso-
ciated phenotype) (LAP) were determined at diagno-
sis in comparison with normal bone marrow cells
from 12 healthy donors or from 15 patients with
expansion of normal precursor B-cells (hematogones)
studied simultaneously and according to the litera-
ture.9,17-24 The LAP used for MRD assessment in our
study are listed in Table 1. The monoclonal antibody
combinations were chosen in each case according to
the type and number of LAP. In 118/140 samples, at
least two combinations (maximum five) were
employed. However 18 samples were tested with
only one monoclonal antibody quadruplet. 
In 69 CD10+ B-cell ALL cases, each combination
included three constant monoclonal antibodies,
CD45-PerCP/CD19-APC/CD10-FITC, and a variable
fourth PE-conjugated monoclonal antibody against
CD20, CD22, CD34, CD38, CD58, CD13 or CD33
antigen. Occasionally, the latter was an anti-CD2,
CD4, CD7, CD15, CD65, CD79b, CD117 or an anti-
Ig l light-chain monoclonal antibody. In seven CD10-
B-cell ALL cases, a CD20-FITC monoclonal antibody
was added to all of the combinations as a fifth anti-
body since CD20 was found to be negative in all of
them. 
The antibody combinations used for T-cell ALL
cases (n=15) were more variable from one case to
another but predominantly included anti-CD3-APC
and CD7-FITC (or CD5-PE) together with CD1a,
CD4, CD8, CD13, CD15, CD33, CD34, CD38,
CD45, CD56, CD117, anti-TCRAB, anti-TCRGD
and/or anti-terminal deoxynucleotidyl transferase
(TdT). All antibodies were purchased from Becton-
Dickinson (San Jose, CA, USA) and Beckman-Coulter
(Miami, FL, USA). Cytoplasmic expression of CD3
(cCD3) and TdT were studied using a two-step pro-
cedure with surface staining by a first set of mono-
clonal antibodies followed by a second incubation of
the cells with a permeabilization reagent
(IntraPrepTM, Beckman-Coulter, Miami, FL, USA) and
anti-CD3 and -TdT monoclonal antibodies. Analyses
were performed with a dual-laser FASCaliburTM flow
cytometer, equipped with Cell Quest ProTM and
PAINT-A-GATE ProTM software (Becton-Dickinson,
San Josè, CA, USA).  
To increase sensitivity and accuracy of the analysis,
acquisition was performed in two consecutive steps.
First, 10000 events were analyzed to determine the
amount of B- (or T-) cells. In the second step, acquisi-
tion through a live gate drawn on the CD19+/side scat-
ter (SSC)low or CD7+ (or CD3+ or CD5+)/SSClow cell
fraction was performed to allow a selective acquisi-
tion (7000 to 100000 events) of B-cells (in B-cell ALL)
or T-cells (in T-cell ALL). Abnormal cell subsets were
then searched and quantified in subsequent gates
drawn on the basis of the LAP characteristics. A clus-
ter of more than 10 dots with aberrant marker
expression was considered as MRD. 
Results
PCR and FC provided highly concordant MRD results
MRD was successfully determined by both PCR
and FC methods in 123 samples and the two meth-
ods provided highly concordant results in 119 of
them (97%). Thus, as shown in Table 2, MRD was
found to be below 0.1% in 86 samples with both
techniques while 20 (17%) results were concordant-
ly positive, including 14 with more than 1% residual
leukemic cells. Thirteen additional MRD determina-
tions were considered negative with both the PCR
and FC techniques although the sensitivity of the
markers used with the former was limited to 0.5%.
According to the follow-up time-point, MRD levels
were identical with both methods in 76/79 (96%)
post-induction and 43/44 (98%) post-consolidation
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Table 1. Number and type of leukemia-associated markers (LAP)
tested for the FC determination of MRD.
Number of B-cell ALL Number of markers T-cell ALL
markers (n= 76) (n= 15)
<2 2 (3%) <2 1 (7%)
2 17 (22%) 2 6 (40%)
≥3 57 (75%) ≥3 8 (53%)
Median (limits) 3 (1-7) Median (limits) 3 (1-5)
Type of markers Type of markers
CD10+bright 40 (53%) CD45+low 9 (60%)
CD34+bright 39 (51%) CD34+ 6 (40%)
CD20– 37 (49%) CD7+bright 5 (33%)
CD22+bright 36 (47%) CD1a+ 4 (27%)
CD38+low 29 (38%) CD13+/CD15+/CD33+/CD117+ 4 (27%)
CD45–/+low 26 (34%) TdT+ 3 (20%)
CD58+bright 24 (32%) CD3- CD4+bright CD8+bright 3 (20%)
CD13+/CD15+/ 23 (30%) CD3+ TCRg/d- CD4– CD8– 3 (20%) 
CD33+/CD65+
CD10– 7 (9%) CD2- CD3+ TCRg/d+ 3 (20%)
CD2+/CD4+/CD7+ 3 (4%) cCD3+ TCRa/b- TCRg/d- 2 (13%)
CD79b+ 2 (3%) CD2– CD3+ CD4– CD8– 2 (13%)
Surface Ig l 1 (1%) CD38- 1 (7%)
light chain+
Results are expressed as number (percentage) of cases with each type of LAP.
LAP include over- (bright fluorescence) or under- (low fluorescence) expressed
antigens by leukemic cells in comparison with their normal counterparts, as well
as illegitimate markers (i.e. markers not expressed by normal cells of the same
lineage). “cCD3”: cytoplasmic CD3. “/”: or 
analyses, including 14 (18%) and 6 (14%) with simi-
larly positive (i.e., >0.1%) MRD. The percentage of
concordant MRD results was similar in samples from
CD10– (9/9, 100%), CD10+ (101/104, 98%) B-cell
ALL and T-cell ALL (9/10, 90%) patients’ subgroups. 
We observed four discordances between PCR and
FC MRD results. Only one of them (MRD at the sec-
ond time-point) was major, since MRD was found to
be positive (0.5-1.0%) with PCR whereas it was
undetectable by FC. Interestingly, MRD was positive
with both methods in the other three samples (all at
the first time-point, but at a lower positivity level
with FC (0.25%, 0.3% and 0.7%) than with PCR
(>1.0%). The former and one of the latter samples
were from the same patient with only one LAP suit-
able for FC analysis. 
PCR and FC are alternative techniques for MRD
detection 
Considering only the results obtained from unse-
lected, consecutive cases (n= 88), MRD could not be
determined by PCR in 10/136 (7%) samples from six
patients, because of absence (three cases: #38, #39,
#59) or oligoclonality (two cases: #47, #48) of IG/TCR
gene rearrangements and because of a very unusual
oligoclonal aspect of the bone marrow taken at the
second time-point from the last patient (#28), as
shown in Tables 3 and 4. In addition, FC was unfea-
sible in four (3%) samples from four patients due to
the lack of a suitable LAP. Interestingly, among these
13 samples for which FC or PCR methods were
unfeasible, MRD measurement was successful with
at least one technique in 12 and unsuccessful with
both in only one sample (at the second time-point)
from an infant with a common pre-B-cell ALL (#28)
and an unusual oligoclonal regenerating bone mar-
row so that the distinction between leukemic and
normal cells was impossible with both techniques.
FC methods would bypass PCR limitations for the
detection of MRD especially in infants, in B-cell ALL
with CD10– phenotype or t(4;11) translocation and
in immature T-cell ALL
Lack of suitable IG/TCR-PCR targets for MRD
monitoring was significantly more frequent in infants
than in older children (3/7, 43% versus 3/81, 4%,
respectively, only unselected cases included)(p<0.01,
c
2 test). As a consequence, MRD determination was
unfeasible with PCR methods in 5/12 (42%) versus
only 5/124 (4%) samples from infants and children,
respectively (p<0.001). Interestingly, FC methods
successfully determined MRD in all of these samples
in which PCR failed except one from an infant (#28)
(Table 3). 
According to immunophenotype, failure of PCR-
MRD determination was significantly more frequent
with samples from CD10– B-cell ALL (4/13, 31%)
than those from CD10+ B-cell ALL (1/106, 1%)
(p<0.01%, c2 test). In all of the patients with CD10–
B-cell ALL, MRD measurements were easily
obtained using FC, given the high number of LAP (3-
7, median: 4). Notably, 5/7 (71%) CD10– B-cell ALL
cases were infants versus only 2/69 (3%) CD10+ B-
cell ALL cases (p<0.001). Moreover, all of the 7
(100%) CD10– B-cell ALL cases but only 1/69 (2%)
CD10+ B-cell ALL were associated with a
t(11q23)/MLL translocation (p<0.001). Among the
former group, five cases presented with a
t(4;11)/MLL-AF4 translocation and a pro-B-cell
(CD10- cIg-, sIg-) immunophenotype. Although two
of them (40%) showed no detectable antigen-recep-
tor gene rearrangement, MRD determination was
efficiently obtained with FC techniques in all of their
nine follow-up samples (Table 3). 
Among 12 consecutive children (17 samples) with
T-ALL, PCR techniques failed in three cases (five
samples). However, FC-MRD determination was
successful in all of them. In contrast, FC methods
Minimal residual disease in childhood ALL
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Table 2. Tandem analysis of MRD with PCR and FC techniques.
Levels FC-MRD: FC-MRD: FC-MRD: FC-MRD:
<0.1% 0.1-1.0% >1.0% failure
CD10– B-cell ALL (13 samples from 7 patients
(including 7 TP1 and 6 TP2 samples)
PCR-MRD: <0.1 4 0 0 0
PCR-MRD:0.1-1.0% 0 1* 0 0
PCR-MRD: >1.0% 0 0 4 0
PCR-MRD: failure 3 1 0 0
CD10+ B-cell ALL (106 samples from 69 patients) 
(including 67 TP1 and 39 TP2 samples)
PCR-MRD: <0.1 79+10* 0 0 1
PCR-MRD:0.1-1.0% 1 5 0 0
PCR-MRD: >1.0% 0 2 7 0
PCR-MRD: failure 0 0 0 1
T-cell ALL (17+4$ samples from 12+3$ patients)
(including 10+1$ TP1 and 7+3$ TP2 samples)
PCR-MRD: <0,1 3+3* 0 0 1
PCR-MRD:0.1-1.0% 0 0 0 1
PCR-MRD: >1.0% 0 1 3 0
PCR-MRD: failure 2+3$ 1+1$ 2 0
all ALL (136+4$ samples from 88+3$ patients)
(including 84+1$ TP1 and 52+3$ TP2 samples)
PCR-MRD: <0.1 86+13* 0 0 2
PCR-MRD:0.1-1.0% 1 5+1* 0 1
PCR-MRD: >1.0% 0 3 14 0
PCR-MRD: failure 5+3$ 2+1$ 2 1
All results are expressed as number of samples from consecutive patients except
for the three cases selectively studied with FC techniques because of failure of PCR
methods (the results of the latter are marked with “ $ ”) .  TP1: time-point 1
(post-induction), TP2: time-point 2 (post-consolidation). Failure: failure of MRD
determination (details in Table 3). *Samples with PCR sensitivity limited to 0.5.
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were inefficient for MRD analysis in two out of four
samples from two other consecutive patients (impos-
sibility to discriminate between normal and leukemic
g/d T-cells), whereas PCR techniques allowed MRD
determination in both samples (Table 4). 
Failure of PCR-MRD determination was signifi-
cantly more frequent in T-cell ALL (5/17, 29%) than
in CD10+ B-cell ALL (1/106, 1%) (p<0.02%, c2 test)
(Table 2). Interestingly, four of these samples in
which TCR-PCR was unsuccessful were from two T-
cell ALL cases with a CD3- CD34+ immature pheno-
type (Table 4). Moreover, two out of three addition-
al, selected patients with unsuccessful TCR-PCR (and
successful FC-MRD determination), also had an
immature T-cell phenotype (Table 4).
Discussion
Our comparative study of MRD monitoring of
childhood ALL confirmed that IGH/TCR-PCR and FC
methods provided highly concordant results. Thus,
the two methods provided 97% concordance of
MRD measurements in our series. This high percent-
age of concordance is comparable to that reported in
some recent series,8,11,14 although the level of MRD
detection used to define MRD positivity was one log
lower in the latter. 
Analysis of the four discordant results in our study
shows that in all cases FC techniques yielded lower
MRD values than PCR but only in one case was
MRD undetectable using FC. These results are in line
with another series by Neale et al.11 who examined 62
samples and found only two discordant results
(weakly positive with PCR but negative with FC). In
a new study extended to 1375 samples from 227 chil-
dren, the same authors reported a variation of esti-
mated MRD level between both techniques in a few
cases.14 Similarly, Malec et al.8 compared the highly
sensitive real-time quantitative-PCR and multicolor
FC methods in 71 childhood ALL follow-up samples
and observed some discordant results, mostly due to
the lower sensitivity of FC. Alternatively, PCR can
overestimate MRD due to DNA from apoptotic
cells.2,25 Another reason for discrepant results is the
Table 3. PCR and FC MRD levels in infants (<1 year old) or in cases with CD10– B-cell ALL.
PN Age Immunophenotype/ PCR Flow cytometry
(years) Cytogenetics
targets TP1-MRD TP2-MRD LAP TP1-MRD TP2-MRD
9 <1 pro-B/CD10– Vg10-JP1JP2 <0.5%£ Not done CD45-low, CD10–, CD20–, CD38+low 0.15% Not done
t(4;11)/MLL-AF4
39 <1 pro-B/CD10– No detectable CD10–, CD15+, CD20–, CD33+, <0.1% <0.1%
t(4;11)/MLL-AF4 IG/TCR gene rearrangements CD34+bright, CD38+low , CD65+
49 <1 pro-B/CD10– Vd2- Dd >1.0% >1.0% CD10–, CD20–, CD34+bright, CD38+low 3.5% 5.0%
t(4;11)/MLL-AF4 2-(I,II)
59 <1 pro-B/CD10– No detectable CD10–, CD20–, CD34+bright, CD58+bright 0.25% <0.1%
t(4;11)/MLL-AF4 IG/TCR gene rearrangements
83 9 pro-B/CD10– Vd2- Dd >1.0% >1.0% CD10–, CD15+, CD20–, 1.2% 2.2%
t(4;11)/MLL-AF4 2- (I,II) CD58+ bright , CD65+
4 1 pre-B /cm+ CD10+ FRIII-JH <0.1% <0.1% CD45+low CD10–, CD20–, CD22+bright
t(9;11)/MLL-AF9 (I,II)
28 <1 common pre-B /CD10+ FRIII-JH <0.1% Oligo° CD20- <0.1% insufficient
t(11;19)/MLL-ENL (I,II) sensitivity#
16 <1 mature B/CD10- sIg+ FRIII-JH <0.1% <0.1% CD10–, CD20–, sIgL+ <0.1% <0.1%
t(9;11)/MLL-AF9 (I,II)
53 <1 mature Tgd VgI-JP1JP2 >1.0% Not (CD2– CD3+ CD4–CD8–) 4.3% 0.26%
(CD3+Tgd+) (I,II) done (CD2– CD3+ Tgd+ CD4– CD8–)
72* <1 mature Tgd Oligoclonality of TCR gene markers (CD45+dim CD2– CD3+ CD4–CD8–) Not 0.22%
(CD3+Tgd+) (CD2– CD3+ Tgd+ CD4– CD8–) done
(CD3+ CD4–CD8– CD15+)
LAP : Leukemia-associated immunophenotype. TP1/TP2-MRD: minimum residual disease level at time-point 1 (or 2). sIgL: surface immunoglobulin l light chain.
*patients from other institutions selected for FC-MRD determination because of failure of PCR methods. £sensitivity of PCR limited to 0.5%; °Oligo: oligoclonality of IGH
markers in TP2  sample, only; #impossibility to distinguish leukemic and normal precursor B-cells (hematogones: 10% of bone marrow mononuclear cells).
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way quantification is performed. In the FC assay, the
proportion of blast cells among total mononuclear
cells in the same sample is measured. In the PCR
assay, the quantity of MRD is derived from a com-
parison to a standard curve made of serial dilutions of
the blasts obtained at diagnosis. This relies on the
assumption that 100% of them contain the marker.
However, when the presence of the marker is
restricted to a subset of blasts (oligoclonality) dis-
playing treatment resistance, the quantity will be
overestimated. We can assume that this has no clini-
cal importance since the bad prognosis is linked to a
slow decrease of the blast population rather than to
the absolute number of residual leukemic cells.
However, in these cases, the MRD result will be
higher than that measured using FC. 
Altogether, these data show that the risk of false
negative MRD results with PCR or FC techniques is
very low. The extension of target panels with mark-
ers expressed on minor sub-clones at diagnosis may
minimize but not suppress false-negative results.10
The use of tandem PCR and FC assays may circum-
vent this risk and ensure MRD monitoring of
ALL.3,11,13,14 
Table 4. PCR and FC MRD levels of T-cell ALL.
UPN age Immunophenotype PCR Flow cytometry
(years) targets TP1-MRD TP2-MRD LAP TP1-MRD TP2-MRD
22* 10 immature T No detectable IGH/TCR gene (cCD3+ Tab-Tdg-CD7+) Not <0.1%
(cCD3+ CD3-) rearrangements (CD3+ CD7+ CD33- CD56-) done
31* 11 immature T No detectable IGH/TCR gene (CD45+dim cCD3+ CD7+ CD34+) <0.1% <0.1%
(cCD3+ CD3- CD34+) rearrangements (CD45+dim cCD3+ CD7+ CD117+)
36 6 immature T Vd2-Dd3 (I,II) >1.0% not (CD45+dim CD7+bright CD3- CD34+) 0.32% not done
(cCD3+ CD3- CD34+) Vd2-Jd1 done (CD45+dim CD7+bright CD3- CD33+)
48 12 immature T Oligoclonality of TCR gene (CD45+dim cCD3+ TdT+) 3.5% 5.0%
(cCD3+ CD3– CD34+) markers (CD45+dim CD7+bright CD3- CD34+)
38 14 immature T No detectable IGH/TCR gene (CD3- CD4+bright CD8+bright ) <0.1% <0.1%
(cCD3+ CD3- CD34+) rearrangements (CD3- CD4+bright CD34+)
47 15 corticothymocytic T Oligoclonality of TCR gene (CD45+dim CD1a+ CD7+bright CD3-) not 0.3%
(CD1a+ CD3–) markers (CD2+ CD3- CD4+bright) done
51 13 corticothymocytic T VgI-J1J2 <0.5%£ not (cCD3+ Tab- Tdg- TdT+) <0.1% <0.1%
(CD1a+ CD3–) (I,II) done (CD45+dim CD7+bright CD3- CD34+)
(CD45+dim CD7+bright CD13+ DR+)
54 13 corticothymocytic T VgI-J1J2 <0.1% not (CD45+dim CD1a+ CD7+ CD3-) <0.1% <0.1%
(CD1a+ CD3–) (I,II) done (CD45+dim CD3- CD4+bright CD8+bright)
71 12 corticothymocytic T VgI-J1J2 <0.5%£ <0.5%£ (cCD3+ TdT+) <0.1% <0.1%
(CD1a+ CD3–) (I,II) (CD1a+ CD3-CD4- CD8+bright)
69 8 corticothymocytic T VgI-J1J2 <0.1% <0.1% (CD45+dim CD1a+ CD3+ Tab-) <0.1% <0.1%
(CD1a+ CD3+) Vg9-J1J2
24 4 mature Tdg Vg9-J1J2 >1.0% <0.1% (CD2- CD3+ CD7+bright Tdg+) 16.00° insufficient
(CD3+Tdg+) (CD2- CD3+ CD5+ Tdg+) sensitivity #
45 4 mature Tdg VgI-J1J2 >1.0% 0.1% (CD3+ T dg+ CD4– CD8–) 2.6% insufficient
(CD3+Tdg+) sensitivity #
53 <1 mature Tdg VgI-JP1JP2 >1.0% Not (CD2– CD3+ CD4– CD8–) 4.3% 0.26%
(CD3+Tdg+) (I,II) done (CD2– CD3+Tdg+ CD4- CD8–)
72* <1 mature Tdg Oligoclonality of TCR genes (CD45+dim CD2– CD3+ CD4–CD8–) not 0.22%
(CD3+Tdg+) markers (CD2– CD3+ Tdg+ CD4- CD8–) done
(CD3+ CD4-CD8- CD15+)
73 15 mature Tdg Vd2-Jd3 0.1-0.5% Not (CD45+dim CD3+dim CD34+CD38–) not <0.1%
(CD3+Tdg+) done (CD45+dim CD2+ CD3+dim CD56–) done
*Patients from other institutions selected for FC-MRD determination because of failure of PCR methods. LAP: leukemia-associated immunophenotype. TP1/TP2-MRD:
minimum residual disease level at time-point 1 (or 2). £sensitivity of PCR limited to 0.5%. °Absence of blast cells on May-Grünwald-Giemsa-stained bone marrow
smears. #Sensitivity of FC markers limited to 1% (LAP difficult to distinguish from normal Tgd cell phenotype).
| 1522 | haematologica/the hematology journal | 2005; 90(11)
N. Robillard et al.
Neither of the two methods can be applied to all
patients. In our series, MRD determination was
unfeasible in 7% of the patients with PCR-based
methods due to the absence or oligoclonality of the
IG, TCRG and TCRD rearrangements. Unfortunately,
the benefit of studying the IGK rearrangement
(prevalent in up to 60% of B-cell ALL)26,27 was weak
since a majority of our patients had T-cell ALL.
Moreover, the CD10– subtype, which accounted for
two of four B-lineage ALL cases without IG heavy
chain and TCR markers had no IGK rearrangement.
A study of rearranged TCRB genes would have been
interesting in T-cell ALL cases. However, the technol-
ogy (i.e. real-time quantitative PCR with allele-spe-
cific oligonucleotides) to do this is complex, expen-
sive and time-consuming.28 Our study shows that
four-color FC is a valuable alternative to PCR. The
applicability of FC was extremely high, since MRD
could be successfully determined in 97% of the sam-
ples, including all but one of those lacking PCR
results. This is in agreement with the large study by
Neale14 in which 99.5% of the patients were
amenable to MRD evaluation with tandem PCR and
FC analysis despite one of the two methods being
unsuitable in 15% of them. 
Recent studies have shown that the incidence of
clonal TCR gene rearrangements in B-cell precursor
ALL varies with age, immunophenotype and geno-
type.27,29-31 In line with these reports, we failed to iden-
tify antigen-receptor gene rearrangements suitable
for PCR-MRD monitoring more frequently in some
ALL subsets including up to 40% of infants, CD10-B-
cell ALL and ALL with t(4;11) translocation (all with
pro-B-cell immunophenotype). Interestingly, FC
techniques allowed easy measurement of MRD in all
but one of these cases. Therefore, FC is a highly effi-
cient alternative to IGH/TCR-PCR in these subsets of
ALL. When feasible, PCR provided concordant MRD
results with FC methods in all of these cases suggest-
ing that IGH/TCR-PCR remained reliable even in
these subsets of ALL.
In our series, it appeared unfeasible to quantify
MRD by PCR in some samples from T-cell ALL cases.
Interestingly, two of the three patients in whom PCR
failed exhibited an immature CD3– CD34+ immuno-
phenotype similar to that of two out of three addi-
tional cases selectively studied with FC methods
because of problematic PCR analysis. This is in
agreement with other reports demonstrating that up
to 50% of immature T-cell ALL still had all TCR
genes in a germ-line configuration.32-34 On the other
hand, FC methods failed to identify suitable LAP in
two additional cases with TCRGD+ T-cell ALL.
However, a tandem strategy eventually succeeded at
determining MRD in all these cases in which PCR or
FC analysis had been unfeasible. An alternative way
to reduce the limitations of FC may be related to new
markers not studied in the current series. 
In this respect, the recent demonstration by
Dworzak et al.24 of broad and stable overexpression
of CD99 on leukemic T cells is highly interesting. We
studied CD99 expression on cryopreserved blasts
from our two T-ALL cases who did not have suitable
LAP and observed that its expression was at least one
log higher than that on normal T-cells from both
patients (data not shown), making this antigen a new
good candidate for FC-MRD studies in T-ALL in the
future. 
We conclude that the MRD results of FC tech-
niques and competitive PCR are strongly concordant.
The applicability of FC appeared higher, especially in
certain subsets of ALL, including ALL in infants and
ALL with an immature B- or T-cell phenotype,
although its appropriateness for outcome prediction
remains to be demonstrated. FC is thus a powerful
alternative to PCR. Further clinical studies including
independent outcome data are required to determine
whether FC may be used instead of PCR as a primary
method for monitoring MRD, especially in the par-
ticular ALL subsets mentioned above. 
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